Clinical Trials Directory

Trials / Terminated

TerminatedNCT00176631

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

A Phase II Trial of Licorice Root and Docetaxel in Patients With Hormone Refractory Prostate Cancer

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Rutgers, The State University of New Jersey · Academic / Other
Sex
Male
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Licorice root extract contains ingredients that may slow the growth of tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving licorice root extract together with docetaxel may be an effective treatment for prostate cancer. PURPOSE: This phase II trial is studying the side effects and how well giving licorice root extract together with docetaxel works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.

Detailed description

OBJECTIVES: Primary * Determine the efficacy and toxicity of licorice root extract in combination with docetaxel in patients with hormone-refractory metastatic prostate cancer. Secondary * Determine the ability of licorice root extract to alter surrogate markers of estrogen activity and cytotoxicity in these patients. OUTLINE: Patients receive docetaxel IV over 1 hour on day 1 and oral licorice root extract 3 times a day on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTlicorice root extractLicorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
DRUGdocetaxelAll the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.

Timeline

Start date
2007-09-01
Primary completion
2008-05-01
Completion
2008-05-01
First posted
2005-09-15
Last updated
2023-12-22
Results posted
2014-01-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00176631. Inclusion in this directory is not an endorsement.